Anti-GTPase HRAS antibody [Y132] (ab32417)
- Product nameAnti-GTPase HRAS antibody [Y132]See all GTPase HRAS primary antibodies ...
- DescriptionRabbit monoclonal [Y132] to GTPase HRAS
- SpecificityReactivity with other RAS members has not, to our knowledge, been tested.
- Tested applicationsWB, ICC/IF, IP more details
- Species reactivityReacts with: Mouse, Rat, Human
Predicted to work with: Chicken
A synthetic peptide corresponding to residues in the C-terminus of human H-Ras.
- Positive controlMCF7 and PC12 cell lysates and MCF7 cells.
- General notesProduced under U.S. Patent No. 5,675,063.
- Storage instructionsShipped at 4°C. Upon delivery aliquot and store at -20°C. Avoid freeze / thaw cycles.
- Storage bufferPBS 49%,Sodium azide 0.01%,Glycerol 50%,BSA 0.05%
- Concentration information loading...
- PurityProtein A purified
- Clonality Monoclonal
- Clone numberY132
Our Abpromise guarantee covers the use of ab32417 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|WB||WB: 1/500. Detects a band of approximately 21 kDa.|
|ICC/IF||ICC/IF: 1/100 - 1/250.|
- FunctionRas proteins bind GDP/GTP and possess intrinsic GTPase activity.
- Involvement in diseaseDefects in HRAS are the cause of faciocutaneoskeletal syndrome (FCSS) [MIM:218040]. A rare condition characterized by prenatally increased growth, postnatal growth deficiency, mental retardation, distinctive facial appearance, cardiovascular abnormalities (typically pulmonic stenosis, hypertrophic cardiomyopathy and/or atrial tachycardia), tumor predisposition, skin and musculoskeletal abnormalities.
Defects in HRAS are the cause of congenital myopathy with excess of muscle spindles (CMEMS) [MIM:218040]. CMEMS is a variant of Costello syndrome.
Defects in HRAS may be a cause of susceptibility to Hurthle cell thyroid carcinoma (HCTC) [MIM:607464]. Hurthle cell thyroid carcinoma accounts for approximately 3% of all thyroid cancers. Although they are classified as variants of follicular neoplasms, they are more often multifocal and somewhat more aggressive and are less likely to take up iodine than are other follicular neoplasms.
Note=Mutations which change positions 12, 13 or 61 activate the potential of HRAS to transform cultured cells and are implicated in a variety of human tumors.
Defects in HRAS are a cause of susceptibility to bladder cancer (BLC) [MIM:109800]. A malignancy originating in tissues of the urinary bladder. It often presents with multiple tumors appearing at different times and at different sites in the bladder. Most bladder cancers are transitional cell carcinomas. They begin in cells that normally make up the inner lining of the bladder. Other types of bladder cancer include squamous cell carcinoma (cancer that begins in thin, flat cells) and adenocarcinoma (cancer that begins in cells that make and release mucus and other fluids). Bladder cancer is a complex disorder with both genetic and environmental influences.
Note=Defects in HRAS are the cause of oral squamous cell carcinoma (OSCC).
- Sequence similaritiesBelongs to the small GTPase superfamily. Ras family.
modificationsPalmitoylated by the ZDHHC9-GOLGA7 complex. A continuous cycle of de- and re-palmitoylation regulates rapid exchange between plasma membrane and Golgi.
S-nitrosylated; critical for redox regulation. Important for stimulating guanine nucleotide exchange. No structural perturbation on nitrosylation.
- Cellular localizationCell membrane. Golgi apparatus membrane. The active GTP-bound form is localized most strongly to membranes than the inactive GDP-bound form (By similarity). Shuttles between the plasma membrane and the Golgi apparatus.
- c bas/has antibodyc H ras antibodyC HA RAS1 antibody
- c has/bas p21 protein antibodyc ras Ki 2 activated oncogene antibodyc ras Ki 2 protein antibodyc-H-ras antibodyCTLO antibodyG1III6 N ras antibodyGTP and GDP binding peptide B antibodyGTPase HRas antibodyGTPase HRas, N-terminally processed antibodyH Ras 1 antibodyH ras oncogene antibodyH RasIDX antibodyH-Ras-1 antibodyHa Ras antibodyHa Ras1 proto oncoprotein antibodyHa-Ras antibodyHAMSV antibodyHRAS 1 antibodyHRAS antibodyHRAS1 antibodyK ras antibodyN ras antibodyp19 H RasIDX protein antibodyp21 protein antibodyp21ras antibodyRas family small GTP binding protein H Ras antibodyRASH 1 antibodyRASH_HUMAN antibodyRASH1 antibodyTransformation gene oncogene HAMSV antibodyTransforming protein p21 antibodyv Ha RAS antibodyv Ha ras Harvey rat sarcoma viral oncogene homolog antibodyVH Ras antibodyvHa RAS antibody
Anti-GTPase HRAS antibody [Y132] images
All lanes : Anti-GTPase HRAS antibody [Y132] (ab32417) at 1/500 dilution
Lane 1 : MCF7 cell lysate
Lane 2 : PC12 cell lysate
Observed band size : 21 kDa (why is the actual band size different from the predicted?)
Immunohistochemical staining of MCF7 cells using ab32417 at 1/100 dilution.
References for Anti-GTPase HRAS antibody [Y132] (ab32417)
This product has been referenced in:
- Lau R et al. cIAP2 represses IKKa/ß-mediated activation of MDM2 to prevent p53 degradation. Cell Cycle 11:4009-19 (2012). Read more (PubMed: 23032264) »
- Yao TW et al. A novel role of dipeptidyl peptidase 9 in epidermal growth factor signaling. Mol Cancer Res 9:948-59 (2011). IP ; Human . Read more (PubMed: 21622624) »